Current trends in West Nile virus vaccine development.

Abstract

West Nile virus (WNV) is a mosquito-borne flavivirus that has become endemic in the United States. From 1999-2012, there have been 37088 reported cases of WNV and 1549 deaths, resulting in a 4.2% case-fatality rate. Despite development of effective WNV vaccines for horses, there is no vaccine to prevent human WNV infection. Several vaccines have been tested in preclinical studies and to date there have been eight clinical trials, with promising results in terms of safety and induction of antiviral immunity. Although mass vaccination is unlikely to be cost effective, implementation of a targeted vaccine program may be feasible if a safe and effective vaccine can be brought to market. Further evaluation of new and advanced vaccine candidates is strongly encouraged.

• Authors: Ian J Amanna, Mark K Slifka
• Journal: Expert review of vaccines (Expert Rev Vaccines) Vol. 13 Issue 5 Pg. 589-608 (May 2014) ISSN: 1744-8395 [Electronic] England
• PMID: 24689659 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Review)

Chemical References

• West Nile Virus Vaccines

Topics

• Animals
• Humans
• Immunization Programs (methods, trends)
• West Nile Fever (epidemiology, prevention & control)
• West Nile Virus Vaccines (administration & dosage)
• West Nile virus (drug effects)